You’ve Been Thinking About ‘Impossible’ All Wrong

Why It Matters

Challenging the status quo turns theoretical roadblocks into commercial opportunities, reshaping biotech pipelines and competitive advantage. Leaders who foster this mindset accelerate breakthrough products and capture emerging market value.

Key Takeaways

• Dantzig solved two famed “unsolvable” statistics problems as homework
• KRAS was labeled untreatable due to its smooth protein surface
• New KRAS inhibitors show previously “undruggable” targets can be hit
• Questioning assumptions fuels leadership‑driven innovation

Pulse Analysis

The story of George Dantzig illustrates a timeless principle: when a problem is labeled impossible, the label often reflects the solver’s mental model, not the problem’s intrinsic difficulty. Dantzig’s accidental encounter with two open statistical questions—mistaken for routine assignments—allowed him to bypass the prevailing belief that they were intractable. By treating them as ordinary homework, he applied standard techniques and produced solutions that stunned the academic community. This anecdote underscores how breaking free from inherited assumptions can generate breakthroughs in any field.

In the biotech arena, the KRAS mutation exemplifies a modern "impossible" that has begun to crumble. For decades, scientists described KRAS as undruggable because its surface lacked obvious binding pockets, likening it to a greasy ball that repels conventional small‑molecule drugs. The development of covalent inhibitors such as sotorasib and adagrasib—targeting the G12C variant—proved that clever molecular design can exploit transient pockets and lock the protein in an inactive state. These drugs have entered late‑stage trials and, in some markets, achieved regulatory approval, opening a multi‑billion‑dollar revenue stream and revitalizing pancreatic‑cancer research pipelines.

The broader lesson for executives and investors is clear: progress often hides behind a veil of assumed impossibility. Companies that institutionalize a culture of questioning—encouraging teams to ask "what if" rather than accepting consensus—are better positioned to capture first‑mover advantage in emerging therapeutic areas. By allocating resources to high‑risk, high‑reward projects and rewarding intellectual curiosity, leaders can transform perceived dead‑ends into growth engines, delivering both societal impact and shareholder value.